Long-term follow-up of facilitated cascade genetic testing for familial cancer syndromes: do at-risk relatives act on the information gained and what are the quality of life implications?

In a pilot study, we found that facilitated cascade genetic testing for cancer-associated pathogenic mutations with telephone counseling and mailed saliva kits resulted in testing of 58% of at-risk relatives (ARRs), significantly higher than prior reports. To ascertain the true value of cascade test...

Full description

Saved in:
Bibliographic Details
Published inGynecologic oncology Vol. 162; pp. S199 - S200
Main Authors Badiner, Nora, Fowlkes, Rana, Nitecki, Roni, Rauh-Hain, Jose, Cornelius-Schecter, Anna, Kahn, Ryan, Chapman-Davis, Eloise, Tubito, Francesca, Christos, Paul, Sharaf, Ravi, Holcomb, Kevin, Lipkin, Steven, Frey, Melissa
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.08.2021
Online AccessGet full text

Cover

Loading…
Abstract In a pilot study, we found that facilitated cascade genetic testing for cancer-associated pathogenic mutations with telephone counseling and mailed saliva kits resulted in testing of 58% of at-risk relatives (ARRs), significantly higher than prior reports. To ascertain the true value of cascade testing, we must determine whether ARRs act upon information gained to prevent cancer morbidity and mortality. We aim to evaluate whether detecting the familial pathogenic mutations in ARRs resulted in utilization of genetically targeted cancer prevention and assess long-term quality of life. ARRs found on cascade genetic testing to harbor a pathogenic mutation were contacted two years following testing for telephone interviews. Interviews focused on utilization of guideline-based cancer preventative medical services, additional testing of family members and quality of life (QOL), assessed via three validated survey instruments (Hospital Anxiety and Depression Scale (HADS), Satisfaction with Decision Scale (SDS) and The Multidimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)). Our pilot trial identified 28 ARRs with pathogenic mutations, among which 25 (89%) were contacted successfully for 2-year follow-up. A total of 4 ARRs (19%) had undergone a total of six risk-reducing surgeries as a result of testing results (hysterectomy with salpingo-oophorectomy-3, salpingo-oophorectomy-1, mastectomy-2). A total of 21 ARRs (75%) underwent 35 cancer surveillance interventions (Figure 1). A total of 5 patients (24%) reported that the genetic results affected their fertility planning and three were considering preimplantation genetic diagnosis. A total of 23 patients (92%) reported sharing their genetic testing results with relatives. A total of 12 patients (52%) reported that their testing resulted in additional testing of relatives. ARRs reported that 14 additional relatives underwent testing, 8 were found to carry the familial mutation, 6 of whom underwent cancer surveillance and one underwent risk-reducing surgery. At 2 years following cascade testing, surveys demonstrated low median levels of anxiety (HADS-A 3, IQR 6) and depression (HADS-D 0, IQR 1) and high levels of satisfaction with testing (MICRA 28, IQR 10, SDS 29, IQR 5). [Display omitted] Long-term follow-up of our pilot study of facilitated cascade testing for cancer-associated pathogenic mutations demonstrates that the majority of ARRs found to carry the familial mutation utilize recommended cancer surveillance interventions and many undergo risk-reducing surgery. Furthermore, we have detected a cascade of the cascade, whereby testing of ARRs leads to iterative rounds of testing of additional relatives who then also have the option for cancer risk reduction. A prospective randomized trial of cascade testing facilitated by the medical team versus standard of care proband-mediated tested is planned and will be critical to shaping the way that the oncology community approaches cascade testing.
AbstractList In a pilot study, we found that facilitated cascade genetic testing for cancer-associated pathogenic mutations with telephone counseling and mailed saliva kits resulted in testing of 58% of at-risk relatives (ARRs), significantly higher than prior reports. To ascertain the true value of cascade testing, we must determine whether ARRs act upon information gained to prevent cancer morbidity and mortality. We aim to evaluate whether detecting the familial pathogenic mutations in ARRs resulted in utilization of genetically targeted cancer prevention and assess long-term quality of life. ARRs found on cascade genetic testing to harbor a pathogenic mutation were contacted two years following testing for telephone interviews. Interviews focused on utilization of guideline-based cancer preventative medical services, additional testing of family members and quality of life (QOL), assessed via three validated survey instruments (Hospital Anxiety and Depression Scale (HADS), Satisfaction with Decision Scale (SDS) and The Multidimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)). Our pilot trial identified 28 ARRs with pathogenic mutations, among which 25 (89%) were contacted successfully for 2-year follow-up. A total of 4 ARRs (19%) had undergone a total of six risk-reducing surgeries as a result of testing results (hysterectomy with salpingo-oophorectomy-3, salpingo-oophorectomy-1, mastectomy-2). A total of 21 ARRs (75%) underwent 35 cancer surveillance interventions (Figure 1). A total of 5 patients (24%) reported that the genetic results affected their fertility planning and three were considering preimplantation genetic diagnosis. A total of 23 patients (92%) reported sharing their genetic testing results with relatives. A total of 12 patients (52%) reported that their testing resulted in additional testing of relatives. ARRs reported that 14 additional relatives underwent testing, 8 were found to carry the familial mutation, 6 of whom underwent cancer surveillance and one underwent risk-reducing surgery. At 2 years following cascade testing, surveys demonstrated low median levels of anxiety (HADS-A 3, IQR 6) and depression (HADS-D 0, IQR 1) and high levels of satisfaction with testing (MICRA 28, IQR 10, SDS 29, IQR 5). [Display omitted] Long-term follow-up of our pilot study of facilitated cascade testing for cancer-associated pathogenic mutations demonstrates that the majority of ARRs found to carry the familial mutation utilize recommended cancer surveillance interventions and many undergo risk-reducing surgery. Furthermore, we have detected a cascade of the cascade, whereby testing of ARRs leads to iterative rounds of testing of additional relatives who then also have the option for cancer risk reduction. A prospective randomized trial of cascade testing facilitated by the medical team versus standard of care proband-mediated tested is planned and will be critical to shaping the way that the oncology community approaches cascade testing.
Author Christos, Paul
Nitecki, Roni
Cornelius-Schecter, Anna
Chapman-Davis, Eloise
Tubito, Francesca
Fowlkes, Rana
Badiner, Nora
Lipkin, Steven
Rauh-Hain, Jose
Holcomb, Kevin
Sharaf, Ravi
Kahn, Ryan
Frey, Melissa
Author_xml – sequence: 1
  givenname: Nora
  surname: Badiner
  fullname: Badiner, Nora
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 2
  givenname: Rana
  surname: Fowlkes
  fullname: Fowlkes, Rana
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 3
  givenname: Roni
  surname: Nitecki
  fullname: Nitecki, Roni
  organization: The University of Texas MD Anderson Cancer Center, Houston, TX, United States
– sequence: 4
  givenname: Jose
  surname: Rauh-Hain
  fullname: Rauh-Hain, Jose
  organization: The University of Texas MD Anderson Cancer Center, Houston, TX, United States
– sequence: 5
  givenname: Anna
  surname: Cornelius-Schecter
  fullname: Cornelius-Schecter, Anna
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 6
  givenname: Ryan
  surname: Kahn
  fullname: Kahn, Ryan
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 7
  givenname: Eloise
  surname: Chapman-Davis
  fullname: Chapman-Davis, Eloise
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 8
  givenname: Francesca
  surname: Tubito
  fullname: Tubito, Francesca
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 9
  givenname: Paul
  surname: Christos
  fullname: Christos, Paul
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 10
  givenname: Ravi
  surname: Sharaf
  fullname: Sharaf, Ravi
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 11
  givenname: Kevin
  surname: Holcomb
  fullname: Holcomb, Kevin
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 12
  givenname: Steven
  surname: Lipkin
  fullname: Lipkin, Steven
  organization: Weill Cornell Medicine, New York, NY, United States
– sequence: 13
  givenname: Melissa
  surname: Frey
  fullname: Frey, Melissa
  organization: Weill Cornell Medicine, New York, NY, United States
BookMark eNqFkU1vVCEYhYmpidOPn2DC0i5Q4MpccNM0jV_JJC5q1-S98DJF74URaJv5bf45malx64pAnnM4OeeUnKSckJDXgr8VXKzf3XJuONNS6TdSXHLBpWHqBVkJbhRba2VOyOof8oqc1vqDcz5wIVfk9yanLWtYFhryPOcn9rCjOdAALs6xQUNPHVQHHukWE7boaMPaYtp2Qenc0jmYO5QcFlr3yZe8YP1AfabQWIn1Jy04Q4uPWCm4RnOi7R5pTN1g6e_9voWY-k-QPH26h0ah4JH59QA9xf6QaI6ha5bdHN1RU6_OycsAc8WLv-cZufv08fvNF7b59vnrzfWGuV6FYiO8l9Mwaqkn0CiMCRNINcEwgTBaaG08hHEIXI5r4GtjlJej7oCWMEinhjOinn1dybUWDHZX4gJlbwW3hwXscQF7qNdKYY8L2IPu6lmHPdxjxGKri9hr8rGga9bn-B-HP_2ik00
ContentType Journal Article
Copyright 2021 Elsevier Inc.
Copyright_xml – notice: 2021 Elsevier Inc.
DBID AAYXX
CITATION
DOI 10.1016/S0090-8258(21)01029-5
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1095-6859
EndPage S200
ExternalDocumentID 10_1016_S0090_8258_21_01029_5
S0090825821010295
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29I
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AAXUO
ABBQC
ABFNM
ABFRF
ABJNI
ABLVK
ABMAC
ABMZM
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AFCTW
AFFNX
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DM4
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HED
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LCYCR
LG5
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OQ.
OZT
P-8
P-9
P2P
PC.
PH~
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSZ
T5K
UDS
UHS
UV1
WUQ
X7M
XPP
Z5R
ZGI
ZMT
ZU3
ZXP
~G-
AAXKI
AAYXX
ACRPL
AFJKZ
AKRWK
CITATION
ID FETCH-LOGICAL-c1025-7a42b37828ba8e199fba25ba3ba1981889daf73f0276a06995d2785ba82a32c53
IEDL.DBID AIKHN
ISSN 0090-8258
IngestDate Fri Dec 06 03:49:46 EST 2024
Fri Feb 23 02:42:36 EST 2024
IsPeerReviewed true
IsScholarly true
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1025-7a42b37828ba8e199fba25ba3ba1981889daf73f0276a06995d2785ba82a32c53
ParticipantIDs crossref_primary_10_1016_S0090_8258_21_01029_5
elsevier_sciencedirect_doi_10_1016_S0090_8258_21_01029_5
PublicationCentury 2000
PublicationDate August 2021
2021-08-00
PublicationDateYYYYMMDD 2021-08-01
PublicationDate_xml – month: 08
  year: 2021
  text: August 2021
PublicationDecade 2020
PublicationTitle Gynecologic oncology
PublicationYear 2021
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0003012
Score 2.397135
Snippet In a pilot study, we found that facilitated cascade genetic testing for cancer-associated pathogenic mutations with telephone counseling and mailed saliva kits...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage S199
Title Long-term follow-up of facilitated cascade genetic testing for familial cancer syndromes: do at-risk relatives act on the information gained and what are the quality of life implications?
URI https://dx.doi.org/10.1016/S0090-8258(21)01029-5
Volume 162
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA66gngRn7i-mIMHPVS3adpNvMgiyuqqB1H0ViZtsy5Iu-xWxYt_zD_nJO36APHgpYWSCWlnmEcz3xfGdpRpibQtIqpNErokHD2peeAZNFpHCk3L8RRcXkXdW3F-H95PseMJFsa2Vda-v_LpzlvXTw7qr3kwHAwsxtce122BnpYXTYXTbIbCkd2rnemc9bpXnw6ZbLgiDXeo6VB-AXmqSdzDXe7vuXm88PcQ9S3snC6w-TpfhE61pEU2leVLbPay3hFfZu8XRd73rH8FQyotXrynIRQGDCYV_3aWQoJj2wUPZCsWsgilZdbI-yQwAveDg2yQBtGrj2DCYDA-hLQALD3bew4V4uU5GwMmJRQ5UNoINeeq1Sz0kVaTAuYpvDxgCTjK3JgKs_lqV_Q4MCTzrYH9aIXdnp7cHHe9-kAGL_HdsbcouA4op5AaZeYrZTTyUGOg0VcU-aVK0bQDQ6VuhK1IqTDlbUkDJMeAJ2Gwyhp5kWdrDALKWzSVowYjKdCnosVQ4SSiNPCFbgnRZPsTHcTDincj_mpII6XFVmkx92OntDhsMjnRVPzDgGKKDX-Lrv9fdIPNcdvk4joCN1mjHD1lW5SllHqbTe-_-du1Ldp77_qu9wHJ8uUt
link.rule.ids 314,780,784,4502,24116,27924,27925,45585,45679
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELUoSJQLKqWIr5Y59ACHwMaxszYXhBBoaXc5gcTNGifxshJKVrsBxIU_xp9j7GS1IFUcesnB8kROZjQzTt57Zuy3dh2Rd0VKe5OMLhnHSFmeRA6dtalG1wk6BYOrtHcj_tzK2wV2NuPCeFhlm_ubnB6ydTty1L7No_Fo5Dm-_rhuT_T0umhafmFLQlL3S0F9-DLHeVAEN5LhgTMt1ZzG09wiDO7z-CDcJZL_LlDvis7FN7badotw2ixojS0U5Xe2PGj_h6-z135VDiOfXcGRQ6un6GEMlQOHWaO-XeSQ4dRj4IEixRMWofa6GuWQDCYQPm9QBNIkevAJzPQLpseQV4B15JHn0PBdHospYFZDVQI1jdAqrnq_whBpNTlgmcPTHdaAkyLMaRibz35F9yNHNu_g6yc_2M3F-fVZL2qPY4iyOBx6i4LbhDoKZVEVsdbOIpcWE4uxprqvdI6umzja6KbYSbWWOe8qmqA4JjyTyQZbLKuy2GSQUNdiaTPqMFUCY3Kao22TSPMkFrYjxBY7nPnAjBvVDTOHo5HTjHea4bEJTjNyi6mZp8yH8DFUGT433f5_0z32tXc96Jv-5dXfHbbCPdwlYAN32WI9eSh-Ur9S218hHt8AsQvkYw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+follow-up+of+facilitated+cascade+genetic+testing+for+familial+cancer+syndromes%3A+do+at-risk+relatives+act+on+the+information+gained+and+what+are+the+quality+of+life+implications%3F&rft.jtitle=Gynecologic+oncology&rft.au=Badiner%2C+Nora&rft.au=Fowlkes%2C+Rana&rft.au=Nitecki%2C+Roni&rft.au=Rauh-Hain%2C+Jose&rft.date=2021-08-01&rft.pub=Elsevier+Inc&rft.issn=0090-8258&rft.eissn=1095-6859&rft.volume=162&rft.spage=S199&rft.epage=S200&rft_id=info:doi/10.1016%2FS0090-8258%2821%2901029-5&rft.externalDocID=S0090825821010295
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon